Whitehawk (WHWK) grants 38,040 stock options to director Aghazadeh

Rhea-AI Filing Summary

Whitehawk Therapeutics, Inc. reported that director and 10% owner Behzad Aghazadeh was granted stock options covering 38,040 shares of common stock. The options have an exercise price of $4.16 per share and expire on June 12, 2036.

According to the terms, all 38,040 underlying shares vest in a single tranche if the reporting person continues to be a service provider through the earlier of the one-year anniversary of the grant date or the day immediately before the next annual shareholder meeting, with a grant date of June 12, 2026. The filing is made jointly by Avoro Capital Advisors LLC, Avoro Ventures LLC, and Dr. Aghazadeh, who each disclaim beneficial ownership beyond their pecuniary interest.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Aghazadeh Behzad, Avoro Capital Advisors LLC, Avoro Ventures LLC

Role null | null | null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	38,040	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 38,040 shares (Direct, null)

Footnotes (1)

1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026. This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro Capital Advisors"), Avoro Ventures LLC, a Delaware limited liability company ("Avoro Ventures") and Behzad Aghazadeh ("Dr. Aghazadeh", and together with Avoro Capital Advisors and Avoro Ventures, the "Reporting Persons"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC. The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Key Figures

Option grant size: 38,040 shares Exercise price: $4.16 per share Expiration date: June 12, 2036 +2 more

5 metrics

Option grant size 38,040 shares Stock option grant on June 12, 2026

Exercise price $4.16 per share Strike price of granted stock options

Expiration date June 12, 2036 Option expiration for 38,040-share grant

Shares underlying options after grant 38,040 shares Total derivative securities following transaction

Vesting schedule 100% cliff vesting Earlier of one year from grant or before next annual meeting

Key Terms

Stock Option (right to buy), 2021 Equity Incentive Plan, Service Provider, beneficial owner, +1 more

5 terms

Stock Option (right to buy) financial

"security_title: Stock Option (right to buy)"

2021 Equity Incentive Plan financial

"as defined in the Issuer's 2021 Equity Incentive Plan"

Service Provider financial

"Subject to the Reporting Person continuing to be a Service Provider"

beneficial owner regulatory

"shall not be deemed an admission that any Reporting Person is the beneficial owner"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

pecuniary interest financial

"disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Aghazadeh Behzad

(Last) (First) (Middle)

C/O AVORO CAPITAL ADVISORS LLC

110 GREENE STREET, SUITE 800

(Street)

NEW YORK NEW YORK 10012

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Whitehawk Therapeutics, Inc. [ WHWK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
	Officer (give title below)	X	Other (specify below)
			See remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

	Form filed by One Reporting Person
X	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.16	06/12/2026		A		38,040		(1)	06/12/2036	Common Stock	38,040	$0	38,040(2)(3)	D

1. Name and Address of Reporting Person^*

Aghazadeh Behzad

(Last) (First) (Middle)

C/O AVORO CAPITAL ADVISORS LLC

110 GREENE STREET, SUITE 800

(Street)

NEW YORK NEW YORK 10012

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)	X	Other (specify below)
			See remarks

1. Name and Address of Reporting Person^*

Avoro Capital Advisors LLC

(Last) (First) (Middle)

110 GREENE STREET, SUITE 800

(Street)

NEW YORK NEW YORK 10012

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)	X	Other (specify below)
			See remarks

1. Name and Address of Reporting Person^*

Avoro Ventures LLC

(Last) (First) (Middle)

110 GREENE STREET, SUITE 800

(Street)

NEW YORK NEW YORK 10012

(City) (State) (Zip)

UNITED STATES

(Country)

Relationship of Reporting Person(s) to Issuer

X	Director	X	10% Owner
	Officer (give title below)	X	Other (specify below)
			See remarks

Explanation of Responses:

1. Subject to the Reporting Person continuing to be a Service Provider (as defined in the Issuer's 2021 Equity Incentive Plan) through such applicable date, one hundred percent (100%) of the shares subject to the option shall vest on the earlier of (i) the one (1) year anniversary of the Date of Grant or (ii) the day immediately prior to the next annual meeting of stockholders following the Date of Grant. "Date of Grant" shall mean June 12, 2026.

2. This Form 4 is filed by Avoro Capital Advisors LLC, a Delaware limited liability company ("Avoro Capital Advisors"), Avoro Ventures LLC, a Delaware limited liability company ("Avoro Ventures") and Behzad Aghazadeh ("Dr. Aghazadeh", and together with Avoro Capital Advisors and Avoro Ventures, the "Reporting Persons"). Dr. Aghazadeh serves as the portfolio manager and controlling person of Avoro Capital Advisors and Avoro Ventures LLC.

3. The filing of this statement shall not be deemed an admission that any Reporting Person is the beneficial owner of the securities reported herein for purposes of Section 16 of the Securities Act of 1934, as amended, or otherwise. Each of the Reporting Persons expressly disclaims beneficial ownership of the securities reported herein except to the extent of its or his pecuniary interest therein.

Remarks:

Avoro Capital Advisors and Avoro Ventures may be deemed directors by deputization of the Issuer by virtue of the fact that Dr. Aghazadeh currently serves on the board of directors of the Issuer.

	/s/ Stephen Rodin, as Attorney-in-Fact	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did the Whitehawk Therapeutics (WHWK) Form 4 disclose?

The Form 4 disclosed a grant of stock options for 38,040 shares of Whitehawk Therapeutics common stock to reporting persons associated with Behzad Aghazadeh, at an exercise price of $4.16 per share, expiring June 12, 2036, as equity-based compensation.

How many Whitehawk Therapeutics (WHWK) options were granted and at what price?

The filing shows a grant of stock options for 38,040 underlying shares of Whitehawk Therapeutics common stock. The options have an exercise price of $4.16 per share, meaning that is the price required to purchase each share upon exercise, subject to vesting.

When do the new Whitehawk Therapeutics (WHWK) options vest?

All 38,040 option shares vest on the earlier of the one-year anniversary of the June 12, 2026 grant date or the day immediately prior to the next annual stockholders’ meeting, provided the reporting person continues as a service provider during this entire vesting period.

Who are the reporting persons in the Whitehawk Therapeutics (WHWK) Form 4?

The reporting persons are Avoro Capital Advisors LLC, Avoro Ventures LLC, and Behzad Aghazadeh. The filing notes that Dr. Aghazadeh is portfolio manager and controlling person of the Avoro entities and that each reporting person disclaims beneficial ownership beyond its or his pecuniary interest.

Does the Whitehawk Therapeutics (WHWK) Form 4 represent a purchase or a grant?

The Form 4 reflects a grant or award acquisition of stock options, coded as transaction type “A” for 38,040 option shares, not an open-market stock purchase or sale. It is compensation-based, with no cash price paid at grant and vesting subject to continued service.